T. Bachelot

Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)

Rosaria Condorelli, Fernanda Mosele, B. Verret et al. · Annals of Oncology · 2019 · 154 citations · Full text

Medicine, Molecular Genetics, Oncology +16

Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer

S.S. Shachar, G. Curigliano, F.P. Duhoux et al. · UNC Libraries · 2021 · 29 citations · Full text

Medicine, Oncology, Pharmacology +12

Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial

P.L. Bedard, C. Anders, Naiheng Lin et al. · UNC Libraries · 2021 · 22 citations · Full text

Medicine, Oncology, Pharmacotherapy +17